Biopharmaceutical characterization of nebulized antimicrobial agents in rats: 1. ciprofloxacin, moxifloxacin, and grepafloxacin

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 7, 2014, Pages 3942-3949

  Gontijo, Aline Vidal Lacerda ^a,c,d   Brillault, Julien ^a,c   Grégoire, Nicolas ^a,c   Lamarche, Isabelle ^a,c   Gobin, Patrice ^a,b   Couet, William ^a,b,c   Marchand, Sandrine ^a,b,c  

^a INSERM   (France)

^b POITIERS UNIVERSITY HOSPITAL   (France)

^c UNIVERSITÉ DE POITIERS   (France)

^d MINISTRY OF EDUCATION OF BRAZIL   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; GREPAFLOXACIN; MOXIFLOXACIN; UREA; AEROSOL; ANTIINFECTIVE AGENT; PIPERAZINE DERIVATIVE; QUINOLONE DERIVATIVE;

AEROSOL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOLYSIS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG EPITHELIAL LINING FLUID LEVEL; DRUG TISSUE LEVEL; DRUG TRANSPORT; DRUG UPTAKE; EPITHELIUM; IN VITRO STUDY; IN VIVO STUDY; LUNG ALVEOLUS MACROPHAGE; LUNG LAVAGE; MACROPHAGE; MALE; NEBULIZATION; NONHUMAN; PRIORITY JOURNAL; RAT; ANIMAL; BRONCHOALVEOLAR LAVAGE FLUID; CELL LINE; CHEMISTRY; HUMAN; INHALATIONAL DRUG ADMINISTRATION; METABOLISM; PHARMACEUTICS; SPRAGUE DAWLEY RAT;

ADMINISTRATION, INHALATION; AEROSOLS; ANIMALS; ANTI-BACTERIAL AGENTS; BIOPHARMACEUTICS; BRONCHOALVEOLAR LAVAGE FLUID; CELL LINE; CIPROFLOXACIN; FLUOROQUINOLONES; HUMANS; MACROPHAGES, ALVEOLAR; MALE; PIPERAZINES; RATS; RATS, SPRAGUE-DAWLEY; UREA;

EID: 84903145255     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02818-14     Document Type: Article

References (41)

1. Hagerman JK, Hancock KE, Klepser ME. 2006. Aerosolised antibiotics: a critical appraisal of their use. Expert Opin. Drug Deliv. 3:71-86. http://dx.doi.org/10.1517/17425247.3.1.71. (Pubitemid 43056392)
2. Michalopoulos AS. 2012. Aerosolized antibiotics: the past, present and future, with a special emphasis on inhaled colistin. Expert Opin. Drug Deliv. 9:493-495. http://dx.doi.org/10.1517/17425247.2012.676039.
3. Michalopoulos A, Papadakis E. 2010. Inhaled anti-infective agents: emphasis on colistin. Infection 38:81-88. http://dx.doi.org/10.1007/s15010-009- 9148-6.
4. Hewer SL. 2012. Inhaled antibiotics in cystic fibrosis: what's new? J. R. Soc. Med. 105 (Suppl 2) : S19-S24. http://dx.doi.org/10.1258/jrsm.2012.12s004.
5. Michalopoulos AS, Falagas ME. 2014. Inhaled antibiotics in mechanically ventilated patients. Minerva Anestesiol. 80:236-244.
6. Dudley MN, Loutit J, Griffith DC. 2008. Aerosol antibiotics: considerations in pharmacological and clinical evaluation. Curr. Opin. Biotechnol. 19:637-643. http://dx.doi.org/10.1016/j.copbio.2008.11.002.
7. Bosquillon C. 2010. Drug transporters in the lung: do they play a role in the biopharmaceutics of inhaled drugs? J. Pharm. Sci. 99:2240-2255. http://dx.doi.org/10.1002/jps.21995.
8. Brillault J, De Castro WV, Couet W. 2010. Relative contributions of active mediated transport and passive diffusion of fluoroquinolones with various lipophilicities in a Calu-3 lung epithelial cell model. Antimicrob. Agents Chemother. 54:543-545. http://dx.doi.org/10.1128/AAC.00733-09.
9. Brillault J, De Castro WV, Harnois T, Kitzis A, Olivier JC, Couet W. 2009. P-glycoprotein-mediated transport of moxifloxacin in a Calu-3 lung epithelial cell model. Antimicrob. Agents Chemother. 53:1457-1462. http://dx.doi.org/10.1128/AAC.01253-08.
10. Westerhout J, Danhof M, De Lange EC. 2011. Preclinical prediction of human brain target site concentrations: considerations in extrapolating to the clinical setting. J. Pharm. Sci. 100:3577-3593. http://dx.doi.org/10.1002/jps. 22604.
11. Campbell L, Abulrob A-NG, Kandalaft LE, Plummer S, Hollins AJ, Gibbs A, Gumbleton M. 2003. Constitutive expression of P-glycoprotein in normal lung alveolar epithelium and functionality in primary alveolar epithelial cultures. J. Pharmacol. Exp. Ther. 304:441-452. http://dx.doi.org/10.1124/jpet.102.042994. (Pubitemid 36008958)
12. Dahyot C, Marchand S, Bodin M, Debeane B, Mimoz O, Couet W. 2008. Application of basic pharmacokinetic concepts to analysis of microdialysis data: illustration with imipenem muscle distribution. Clin. Pharmacokinet. 47:181-189. http://dx.doi.org/10.2165/00003088-200847030-00004.
13. National Research Council. 2011. Guide for the care and use of laboratory animals, 8th ed. National Academies Press, Washington, DC.
14. Marchand S, Gobin P, Brillault J, Baptista S, Adier C, Olivier JC, Mimoz O, Couet W. 2010. Aerosol therapy with colistin methanesulfonate: a biopharmaceutical issue illustrated in rats. Antimicrob. Agents Chemother. 54:3702-3707. http://dx.doi.org/10.1128/AAC.00411-10.
15. Krombach F, Munzing S, Allmeling AM, Gerlach JT, Behr J, Dorger M. 1997. Cell size of alveolar macrophages: an interspecies comparison. Environ. Health Perspect. 105(Suppl 5):S1261-S1263.
16. Hemanth Kumar AK, Ramachandran G. 2009. Simple and rapid liquid chromatography method for determination of moxifloxacin in plasma. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 877:1205-1208. http://dx.doi.org/10.1016/j.jchromb.2009.02.042.
17. Rennard SI, Basset G, Lecossier D, O'Donnell KM, Pinkston P, Martin PG, Crystal RG. 1986. Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution. J. Appl. Physiol. 60:532-538. (Pubitemid 16019939)
18. Kiem S, Schentag JJ. 2008. Interpretation of antibiotic concentration ratios measured in epithelial lining fluid. Antimicrob. Agents Chemother. 52:24-36. http://dx.doi.org/10.1128/AAC.00133-06.
19. Bulitta JB, Bingolbali A, Shin BS, Landersdorfer CB. 2011. Development of a new pre- and post-processing tool (SADAPT-TRAN) for nonlinear mixed-effects modeling in S-ADAPT. AAPS J. 13:201-211. http://dx.doi.org/10.1208/s12248-011- 9257-x.
20. Roosendaal R, Bakker-Woudenberg IA, van den Berghe-van Raffe M, Vink-van den Berg JC, Michel MF. 1987. Comparative activities of ciprofloxacin and ceftazidime against Klebsiella pneumoniae in vitro and in experimental pneumonia in leukopenic rats. Antimicrob. Agents Chemother. 31:1809-1815. http://dx.doi.org/10.1128/AAC.31.11.1809. (Pubitemid 17157649)
21. Siefert HM, Domdey-Bette A, Henninger K, Hucke F, Kohlsdorfer C, Stass HH. 1999. Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: a comparison in humans and other mammalian species. J. Antimicrob. Chemother. 43:69-76. http://dx.doi.org/10.1093/jac/43.suppl-2.69. (Pubitemid 29231796)
22. Beal SL. 2001. Ways to fit a PK model with some data below the quantification limit. J. Pharmacokinet. Pharmacodyn. 28:481-504. http://dx.doi.org/10.1023/A:1012299115260. (Pubitemid 33151426)
23. Mouton JW, Theuretzbacher U, Craig WA, Tulkens PM, Derendorf H, Cars O. 2008. Tissue concentrations: do we ever learn? J. Antimicrob. Chemother. 61:235-237. http://dx.doi.org/10.1093/jac/dkm476.
24. Marchand S, Frasca D, Dahyot-Fizelier C, Breheret C, Mimoz O, Couet W. 2008. Lung microdialysis study of levofloxacin in rats following intravenous infusion at steady state. Antimicrob. Agents Chemother. 52:3074-3077. http://dx.doi.org/10.1128/AAC.00242-08.
25. Dhanani J, Roberts JA, Chew M, Lipman J, Boots RJ, Paterson DL, Fraser JF. 2010. Antimicrobial chemotherapy and lung microdialysis: a review. Int. J. Antimicrob. Agents 36:491-500. http://dx.doi.org/10.1016/j.ijantimicag.2010.08. 013.
26. Deguchi Y, Sun J, Tauchi Y, Sakai S, Morimoto K. 2003. Distribution characteristics of grepafloxacin, a fluoroquinolone antibiotic, in lung epithelial lining fluid and alveolar macrophage. Drug Metab. Pharmacokinet. 18:319-326. http://dx.doi.org/10.2133/dmpk.18.319.
27. Hamishehkar H, Emami J, Najafabadi AR, Gilani K, Minaiyan M, Hassanzadeh K, Mahdavi H, Koohsoltani M, Nokhodchi A. 2010. Pharmacokinetics and pharmacodynamics of controlled release insulin loaded PLGA microcapsules using dry powder inhaler in diabetic rats. Biopharm. Drug Dispos. 31:189-201. http://dx.doi.org/10.1002/bdd.702.
28. Togami K, Chono S, Morimoto K. 2011. Distribution characteristics of clarithromycin and azithromycin, macrolide antimicrobial agents used for treatment of respiratory infections, in lung epithelial lining fluid and alveolar macrophages. Biopharm. Drug Dispos. 32:389-397. http://dx.doi.org/10. 1002/bdd.767.
29. Strohl KP, Thomas AJ, St Jean P, Schlenker EH, Koletsky RJ, Schork NJ. 1997. Ventilation and metabolism among rat strains. J. Appl. Physiol. 82:317-323. http://dx.doi.org/10.1063/1.365814. (Pubitemid 27052077)
30. Michot JM, Seral C, Van Bambeke F, Mingeot-Leclercq MP, Tulkens PM. 2005. Influence of efflux transporters on the accumulation and efflux of four quinolones (ciprofloxacin, levofloxacin, garenoxacin, and moxifloxacin) in J774 macrophages. Antimicrob. Agents Chemother. 49:2429-2437. http://dx.doi.org/10. 1128/AAC.49.6.2429-2437.2005. (Pubitemid 40734476)
31. Carryn S, Van Bambeke F, Mingeot-Leclercq MP, Tulkens PM. 2002. Comparative intracellular (THP-1 macrophage) and extracellular activities of -lactams, azithromycin, gentamicin, and fluoroquinolones against Listeria monocytogenes at clinically relevant concentrations. Antimicrob. Agents Chemother. 46:2095-2103. http://dx.doi.org/10.1128/AAC.46.7.2095-2103.2002. (Pubitemid 34665902)
32. Hara T, Takemura H, Kanemitsu K, Yamamoto H, Shimada J. 2000. Comparative uptake of grepafloxacin and ciprofloxacin by a human monocytic cell line, THP-1. J. Infect. Chemother. 6:162-167. http://dx.doi.org/10.1007/s101560070016.
33. Gotfried MH, Danziger LH, Rodvold KA. 2001. Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects. Chest 119:1114-1122. http://dx.doi.org/10.1378/chest.119.4.1114. (Pubitemid 32679439)
34. Schuler P, Zemper K, Borner K, Koeppe P, Schaberg T, Lode H. 1997. Penetration of sparfloxacin and ciprofloxacin into alveolar macrophages, epithelial lining fluid, and polymorphonuclear leucocytes. Eur. Respir. J. 10:1130-1136. http://dx.doi.org/10.1183/09031936.97.10051130. (Pubitemid 27201821)
35. Baldwin DR, Wise R, Andrews JM, Gill M, Honeybourne D. 1993. Comparative bronchoalveolar concentrations of ciprofloxacin and lomefloxacin following oral administration. Respir. Med. 87:595-601. http://dx.doi.org/10.1016/S0954- 6111(05)80262-8. (Pubitemid 23350168)
36. Capitano B, Mattoes HM, Shore E, O'Brien A, Braman S, Sutherland C, Nicolau DP. 2004. Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults. Chest 125:965-973. http://dx.doi.org/10.1378/chest.125.3.965. (Pubitemid 38367287)
37. Soman A, Honeybourne D, Andrews J, Jevons G, Wise R. 1999. Concentrations of moxifloxacin in serum and pulmonary compartments following a single 400 mg oral dose in patients undergoing fibre-optic bronchoscopy. J. Antimicrob. Chemother. 44:835-838. http://dx.doi.org/10.1093/jac/44.6.835.
38. Cook PJ, Andrews JM, Wise R, Honeybourne D, Moudgil H. 1995. Concentrations of OPC-17116, a new fluoroquinolone antibacterial, in serum and lung compartments. J. Antimicrob. Chemother. 35:317-326. http://dx.doi.org/10. 1093/jac/35.2.317.
39. Gontijo AVL, Grégoire N, Lamarche I, Gobin P, Couet W, Marchand S. 2014. Biopharmaceutical characterization of nebulized antimicrobial agents in rats: 2. Colistin. Antimicrob. Agents Chemother. 58:3950-3956. http://dx.doi.org/10.1128/AAC.02819-14.
40. Conte JE, Jr, Golden J, Duncan S, McKenna E, Lin E, Zurlinden E. 1996. Single-dose intrapulmonary pharmacokinetics of azithromycin, clarithromycin, ciprofloxacin, and cefuroxime in volunteer subjects. Antimicrob. Agents Chemother. 40:1617-1622. (Pubitemid 26227345)
41. Sabet M, Miller CE, Nolan TG, Senekeo-Effenberger K, Dudley MN, Griffith DC. 2009. Efficacy of aerosolMP-376,a levofloxacin inhalation solution, inmodels of mouse lung infection due to Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 53:3923-3928. http://dx.doi.org/10.1128/AAC.00268-09.